Skip to content

IDEAI participates in DIALCAT

DIALCAT is an EU-funded project that aims to prevent Alzheimer's disease in patients with diabetes
IDEAI participates in DIALCAT

IDEAI members participate in the EU funded project DIALCAT. The project is based on epidemiological data confirming that patients with diabetes have 2 to 3 times higher prevalence of severe cognitive impairment and Alzheimer’s disease than non-diabetic population comparable in age. To address this reality, the project proposes a comprehensive approach ranging from basic to clinical observational research, and it includes a pilot intervention study. The IDEAI center, in collaboration with the GRINS research group, has developed a smart pill dispenser to support and monitorize the treatment adherence of the study partcipants. The interventional pilot study will be deployed in the Catalonia region at the beginning of 2019.

 

Objective: Prevention of Alzheimer disease in patients with diabetes

Innovation: Multidisciplinary and comprehensive approach to treatment intelligence

Expected result: Obtaining an intelligent dispenser prototype and a digital platform integrating data for the identification of risk profiles

Financing: This project has received funding from the European Union through The European Regional Development Funds (ERDF)

Project Budget: 2’500’000 €

Financial Framework: RIS3CAT

Contract number: COMRDI15-1-0024-08

Start Date: 15/10/2016

End Date: 30/04/2020

Contact Manager: Cristian Barrue - cbarrue@cs.upc.edu

Coordinator:

Intelligent_pharma.png

Partners:

Fede_farma.png    Anaxomics.png    Meditecnologia.png

Mixestat.png    Mutua_terrassa.png    Pere_Virgili.png

Vall_Hebron.png    Leitat.png    CVH.png

 UPC.png Althaia.jpg FUB.jpg Hospital_granollers.jpeg Promax.png

Fons_eu_desenvolupament_regional.png    Accio.png    Generalitat_catalunya.png